ArticleNature immunology2022
CD66b
Article in Nature immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 64 citations in OpenAlex.
- Granulocyte heterogeneity in immune-mediated and inflammatory diseases: insights from single-cell transcriptomic analyses.International immunology · 2026Review
- Human immunosuppressive neutrophils: recent answers to old and new questions.The EMBO journal · 2026Review
- Harnessing myeloid cell plasticity for cancer therapy.Nature cancer · 2026Review
- Matrix-bound nanovesicles as epigenetic modulators of myeloid cells.Science advances · 2026Article
- Spatiotemporal dynamics of tumor-associated neutrophils: bridging the gap between cancer progression and immunotherapy.Molecular cancer · 2026Review
- The neutrophil collective.Cell · 2025Review
- Myeloid metabolism and its role in immunotherapy of cancer.Journal for immunotherapy of cancer · 2025Review
- Neutrophil maturation holds the secret to human tumor suppression.Cell research · 2025Article
- Targeting neutrophils for cancer therapy.Nature reviews. Drug discovery · 2025Review
- Target neutrophil heterogeneity and plasticity in cancer.Journal of hematology & oncology · 2025Review
- Human myelocyte and metamyelocyte-stage neutrophils suppress tumor immunity and promote cancer progression.Cell research · 2025Article
- On the origin of neutrophils.Cellular & molecular immunology · 2025Article
- Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis.Cellular & molecular immunology · 2025Article
- Exploring Neutrophil Heterogeneity and Plasticity in Health and Disease.Biomedicines · 2025Review
- The impact of aging on neutrophil functions and the contribution to periodontitis.International journal of oral science · 2025Review
- Highly Selective Exogenous Neutrophils Effectively Inhibit Growth of Colon Cancer under the Guidance of Precision Navigation.Research (Washington, D.C.) · 2025Article
- The success of the tumor immunotherapy: neutrophils from bench to beside.Frontiers in immunology · 2025Review
- Neutrophil diversity and function in health and disease.Signal transduction and targeted therapy · 2024Review
- Regulation of neutrophil associated RNASET2 expression in rheumatoid arthritis.Scientific reports · 2024Article
- Neutrophil Diversity (Immature, Aged, and Low-Density Neutrophils) and Functional Plasticity: Possible Impacts of Iron Overload in β-Thalassemia.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we report the identification of human CD66b
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.